GlassScriptPhysician profile
Peter Lawrence Fort
NPI 1932191319
$1,327.70
in general payments reported to CMS, 2019-2025
22 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.93 · 2020: $80.11 · 2021: $10.00 · 2022: $276 · 2023: $164 · 2024: $201 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.85 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.08 | 2022-2024 | Ofev |
| Grifols USA, LLC | $171.54 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $125.20 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $86.15 | 2023-2025 | Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $85.53 | 2022-2025 | Glassia |
| Insmed, INC. | $84.13 | 2022-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $78.58 | 2019-2023 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $73.34 | 2019-2025 | Trelegy Ellipta, Nucala |
| Merck Sharp & Dohme LLC | $64.97 | 2023-2025 | Winrevair |
| Pulmonx Corporation | $53.54 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Mylan Specialty L.P. | $45.90 | 2022-2024 | Yupelri |
| Chiesi USA, INC. | $45.61 | 2019-2020 | |
| Viatris Specialty LLC | $34.55 | 2025 | Yupelri |
| Fisher & Paykel Healthcare INC | $30.55 | 2022-2024 | Fisher & Paykel Healthcare |
| Baxter Healthcare | $28.34 | 2022-2025 | Hillrom - Volara System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Breas Medical, INC. | $25.89 | 2025 | Vivo 45 Ls |
| Csl Behring | $24.46 | 2020 | |
| Genzyme Corporation | $22.09 | 2025 | |
| Inspire Medical Systems, INC. | $13.73 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $12.87 | 2019 | |
| Olympus America INC. | $12.65 | 2022 | |
| United Therapeutics Corporation | $10.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Fort listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.